MS fatigue in relapsing-remitting disease was linked to pain, sleep problems, anxiety, stress, and disability in a ...

Fingolimod represents a first-in-class oral sphingosine-1-phosphate receptor modulator approved for adults with relapsing-remitting multiple sclerosis (RRMS). By sequestering lymphocytes in lymphoid ...

People with relapsing-remitting MS may have less diverse gut bacteria, with shifts in genes involved in virulence, per a ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Kessler Foundation researchers have demonstrated for the first time ever that body temperature is elevated endogenously in relapsing-remitting multiple sclerosis (RRMS) and linked to worse fatigue.

A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows ...

The latest advances in relapsing-remitting multiple sclerosis (RRMS) presented at the 2026 American Academy of Neurology Annual Meeting include a promising potential new treatment and several studies ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

European Commission approves Aubagio ® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis PARIS – ...

I got married in 2014. I remember waking up with numb feet a couple months after we bought our house. But I didn’t think much of it at the time. I could always feel the floor again once I’d finished ...